Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7897 - 7904 of 12104 results
Summer Round-Up: Four States Bolster Data Breach Notification Laws and More Changes on the Way
September 2, 2016| Blog| Viewpoint
Final Rule Boosts Health-Care Penalties to Reflect Inflation
September 2, 2016| News
ITC Declines to File Petition for Certiorari – CAFC Holding that ITC Does Not Have Jurisdiction over Digital Imports Stands
September 1, 2016| Blog| Viewpoint
FDA Announces Dates for Long-Awaited Public Hearing on Its Regulation of Off-Label Communications
September 1, 2016| Blog| Viewpoint
What Does It Mean to be a Champion for Each Other’s Success?
September 1, 2016| News
EB-5 Reauthorization Heading into Lame Duck Session of Congress
September 1, 2016| Blog| Viewpoint
National Labor Relations Board Grants Student Assistants the Right to Unionize at Private Colleges and Universities
August 31, 2016| Blog| Viewpoint
Preparing for an Exit: Selling Your Robotics Company
August 31, 2016| Article| Viewpoint
News & Press Releases
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|